补肺化瘀汤联合吉非替尼治疗非小细胞肺癌临床研究
CSTR:
作者:
中图分类号:

R734.2

基金项目:

河南省中医药科学研究专项课题(2016ZY3049)


Clinical Study of Bufei Huayu Prescription Combined with Gefitinib for Non-Small Cell Lung Cancer
  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • | |
  • 文章评论
    摘要:

    目的:观察补肺化瘀汤联合吉非替尼治疗非小细胞肺癌(NSCLC) 的临床疗效及对免疫功能、血清一氧化氮(NO) 和血管内皮生长因子(VEGF) 水平的影响。方法:选取90 例肺脾气虚型表皮生长因子受体(EGFR) 基因突变晚期NSCLC 患者,按随机数字表法分为对照组和观察组各45 例。对照组给予吉非替尼治疗,观察组在对照组基础上给予补肺化瘀汤治疗。比较2 组临床疗效和治疗前后中医证候积分、生活质量、外周血T 淋巴细胞水平和血清NO、VEGF 水平,并观察不良反应发生情况。结果:观察组疾病控制率为71.11%,高于对照组44.44%,差异有统计学意义(P<0.05)。治疗后,2 组中医证候积分较治疗前降低,Karnofsky 评分(KPS) 评分较治疗前提高(P<0.05);且观察组中医证候积分低于对照组,KPS 评分高于对照组(P<0.05)。治疗后,2 组外周血CD3+、CD4+、CD4+/CD8+较治疗前提高,CD8+较治疗前降低(P<0.05);且观察组外周血CD3+、CD4+、CD4+/CD8+高于对照组,CD8+低于对照组(P<0.05)。治疗后,2 组血清NO、VEGF 水平较治疗前降低(P<0.05),且观察组血清NO、VEGF 水平低于对照组(P<0.05)。观察组腹泻、恶心呕吐、皮疹、脱发发生率明显低于对照组(P<0.05)。结论:补肺化瘀汤联合吉非替尼治疗肺脾气虚型EGFR 基因突变晚期NSCLC 疗效确切,可改善临床症状,提高免疫功能和生活质量,降低血清NO、VEGF 表达,减轻毒副作用。

    Abstract:

    Abstract:Objective:To observe the clinical effect of Bufei Huayu prescription combined with gefitinib for non-small cell lung cancer(NSCLC) and its effects on immune function and levels of serum nitric oxide (NO) and vascular endothelial growth factor(VEGF). Methods: A total of 90 cases of patients who had advanced NSCLC with epidermal growth factor receptor(EGFR) gene mutation and of the lung- spleen qi deficiency type were selected and divided into the control group and the observation group according to the random number table method,with 45 cases in each group. The control group was treated with gefitinib, and the observation group was treated with Bufei Huayu tang and gefitinib. Chinese medicine syndrome scores, quality of life, levels of T lymphocyte in peripheral blood, and levels of NO and VEGF in serum before and after treatment,as well as clinical effects were compared between the two groups. Incidence of adverse reactions was observed. Results: The disease controlling rate was 71.11% in the observation group, higher than that of 44.44% in the control group, the difference being significant(P<0.05). After treatment, Chinese medicine syndrome scores in the two groups were decreased when compared with those before treatment,and Karnofsky scores(KPS) in the two groups were increased(P<0.05);Chinese medicine syndrome score in the observation group was lower than that in the control group,and KPS score was higher(P<0.05). After treatment,CD3+,CD4+,and CD4+/CD8+ in peripheral blood in the two groups were increased when compared with those before treatment,and CD8+ were decreased(P<0.05);CD3+, CD4 +,and CD4 +/CD8 + in peripheral blood in the observation group were higher than those in the control group,and CD8+ was lower(P<0.05). After treatment,levels of NO and VEGF in serum in the two groups were decreased when compared with those before treatment(P<0.05), and the two levels in the observation group were lower than those in the control group(P<0.05). The incidence of diarrhea,nausea and vomiting, rash and alopecia in the observation group was significantly lower than that in the control group(P<0.05). Conclusion:Bufei Huayu tang combined with gefitinib has a defined curative effect in the treatment of NSCLC with EGFR gene mutation and of the lung- spleen qi deficiency type, which can improve clinical symptoms, immune function and quality of life, and reduce NO in serum, VEGF expression and toxic and side effects.

    参考文献
    相似文献
    引证文献
引用本文

贾磊,张跃强,曾祥学.补肺化瘀汤联合吉非替尼治疗非小细胞肺癌临床研究[J].新中医,2022,54(17):192-196

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 在线发布日期: 2022-09-06
文章二维码